Compare SHIM & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHIM | GNLX |
|---|---|---|
| Founded | 1990 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.2M | 133.0M |
| IPO Year | 2023 | 2022 |
| Metric | SHIM | GNLX |
|---|---|---|
| Price | $3.73 | $2.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 80.0K | ★ 279.5K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.95 | 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $492,844,000.00 | $8,000.00 |
| Revenue This Year | $13.99 | N/A |
| Revenue Next Year | $6.94 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.63 | N/A |
| 52 Week Low | $1.95 | $2.29 |
| 52 Week High | $6.76 | $8.54 |
| Indicator | SHIM | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 43.93 | 46.01 |
| Support Level | $3.44 | $2.39 |
| Resistance Level | $4.09 | $3.05 |
| Average True Range (ATR) | 0.29 | 0.20 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 6.88 | 37.93 |
Shimmick Corp is engaged in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains critical infrastructure, including mass transit, bridges, and military infrastructure. The company has one operating and reportable segment: infrastructure solutions. All of its revenue is derived from the United States.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.